XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
  Anti-Inflammatory
  Antivirals
  Antihypertensives
  Anticholesterol
  Anti-Clotting Drugs
  Anti Cancer Drugs
  Hypnotics
  PPI
  Antibiotics
  Analgesics
  Surfactants
  Fatty Acids
  Adrenergics
  Metals
  Varenicline
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Aug 19th, 2006 - 22:18:38

Anti-Clotting Drugs Channel
subscribe to Anti-Clotting Drugs newsletter

Latest Research : Pharmacology : Anti-Clotting Drugs

   DISCUSS   |   EMAIL   |   PRINT
New 'designer' drugs in anti-clotting technology
Dec 13, 2005, 22:05, Reviewed by: Dr. Rashmi Yadav

"This class of drugs is a very promising technology that allows for the development of 'designer' drugs and their antidotes simultaneously. It could have far-reaching implications."


 
Volunteers at the Jack and Linda Gill Heart Institute at the University of Kentucky were the first ever to receive a new anti-clotting therapy. The drug and its antidote are being developed for their effectiveness in preventing blood clots while at the same time providing physicians the ability to rapidly reverse the effects of the blood thinner to help safeguard patients against uncontrolled bleeding.

More than 12 million patients are prescribed so-called "blood thinners" each year to prevent the formation of clots, which can block blood vessels, causing heart attacks, strokes and other debilitating or life-threatening conditions. Blood thinners, or antithrombotics, pose a risk of bleeding, particularly during surgery. The ability to stop the anti-clotting effects quickly could help protect patients from uncontrolled bleeding.

The Gill Heart Institute is one of two sites participating in the Phase 1 trial and is the first site to use the anti-clotting drug and its antidote.

This clinical trial will examine the drug's safety and tolerability in healthy volunteers as well as the antidote's ability to quickly reverse its effects. Although other new antithrombotics are undergoing testing in the U.S., this drug is believed to be the first of its kind.

"This class of drugs is a very promising technology that allows for the development of 'designer' drugs and their antidotes simultaneously," said Dr. Steven R. Steinhubl, the study's principal investigator at UK and director of cardiovascular education and clinical research at the Gill Heart Institute and a UK College of Medicine associate professor of cardiology. "It could have far-reaching implications."

"The research capacity of the cardiology division at UK has skyrocketed in the last year. Millions of dollars in research projects are under way, and we have attracted world-recognized leaders in drug discovery and development, such as Dr. Steinhubl. Leaders of technology and pharmaceutical companies have visited us in Lexington and are entrusting us to pioneer the next-generation of medicines and devices to improve healthcare," said Dr. David Moliterno, professor and vice chair of medicine, and chief, division of cardiovascular medicine, UK College of Medicine, and co-director of the UK Gill Heart Institute.

"Our goal is simple: we want to help patients with heart and vascular disorders by being at the forefront. Our research efforts are clearly bringing Kentuckians closer to the leading edge of the best medicine has to offer," Moliterno said.
 

- The Gill Heart Institute
 

www.uky.edu/

 
Subscribe to Anti-Clotting Drugs Newsletter
E-mail Address:

 

The UK Linda and Jack Gill Heart Institute provides a central focus for cardiovascular disease care, including clinics; non-invasive cardiac diagnostics; invasive cardiac techniques such as cardiac catheterization, angioplasty and electrophysiology; a base for the physicians providing this care and a special focus on counseling cardiac patients and their families. The clinical programs of the institute target the high rate of heart disease prevalent in Kentucky, while the research and teaching programs work to advance cardiovascular care throughout the world.

The institute has its origins in the 1997 donation of $5 million from Linda and Jack Gill of Houston, Texas, to UK to build the Gill Heart Institute facility and establish three endowed chairs and 10 endowed professorships. Matching funds from the Kentucky Research Challenge Trust Fund augmented the Gills' donation.

In striving to become a Top-20 public research institution, the University of Kentucky is a catalyst for a new Commonwealth � a Kentucky that is healthier, better educated, and positioned to compete in a global and changing economy. For more information about UK's efforts to become a Top-20 university, please go to http://www.uky.edu/OPBPA/Top20.html

Contact: Beth Goins
[email protected]
859-327-0078
University of Kentucky


Related Anti-Clotting Drugs News

Desensitization protocol overcomes allergy to clopidogrel
New 'designer' drugs in anti-clotting technology
FDA Approves Fondaparinux sodium for Prevention of Venous Thromboembolism in Abdominal Surgery
New Class of Anticlotting Drugs Discovered


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us